Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Canine alpha Synuclein ELISA Kit (AC3120)
Cat.#: ASET-1709
Specifications
Description Canine alpha Synuclein ELISA Kit allows for the in vitro quantitative determination of canine alpha Synuclein concentrations in serum, plasma, tissue homogenates, and other biological fluids. The kit employs the sandwich enzyme immunoassay technique. Size 96T Sample Type Serum, plasma, tissue homogenates, and other biological fluids. Reactivity Canine Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 9.375 pg/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 15.625-1000 pg/mL Assay Time 4h 30m Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1232 Human NENF ELISA Kit (AC2643) Quantitative inquiry ASET-1894 Human FGFR4 ELISA Kit (AC3305) Quantitative inquiry ASET-1084 Mouse C1qtnf5 ELISA Kit (AC2495) Quantitative inquiry ASET-1462 Human Salusin alpha ELISA Kit (AC2873) Quantitative inquiry ASET-1245 Human CYP1B1 ELISA Kit (AC2656) Quantitative inquiry ASET-2403 Human FGF2 ELISA Kit (AC3814) Quantitative inquiry ASET-1856 Mouse P Cadherin ELISA Kit (AC3267) Quantitative inquiry ASET-2392 Mouse Huntingtin ELISA Kit (AC3803) Quantitative inquiry ASET-2050 Human MAL ELISA Kit (AC3461) Quantitative inquiry ASET-1535 Rat Prostate Specific Antigen ELISA Kit (AC2946) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket